These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34623627)

  • 1. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
    Wang Y; Luangasanatip N; Pan-Ngum W; Isaranuwatchai W; Prawjaeng J; Saralamba S; Painter C; Briones JR; Teerawattananon Y
    Eur J Health Econ; 2023 Jul; 24(5):735-748. PubMed ID: 35951243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for the economic evaluation of COVID-19 pandemic response policies.
    Chua BWB; Huynh VA; Lou J; Goh FT; Clapham H; Teerawattananon Y; Wee HL
    BMJ Open; 2021 Sep; 11(9):e051503. PubMed ID: 34521677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis.
    Wu JT; Jit M; Zheng Y; Leung K; Xing W; Yang J; Liao Q; Cowling BJ; Yang B; Lau EH; Takahashi S; Farrar JJ; Grenfell BT; Leung GM; Yu H
    PLoS Med; 2016 Mar; 13(3):e1001975. PubMed ID: 26978565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model.
    Choi W; Shim E
    Front Public Health; 2023; 11():1280412. PubMed ID: 38074736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Jentsch PC; Anand M; Bauch CT
    Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
    Orangi S; Ojal J; Brand SP; Orlendo C; Kairu A; Aziza R; Ogero M; Agweyu A; Warimwe GM; Uyoga S; Otieno E; Ochola-Oyier LI; Agoti CN; Kasera K; Amoth P; Mwangangi M; Aman R; Ng'ang'a W; Adetifa IM; Scott JAG; Bejon P; Keeling MJ; Flasche S; Nokes DJ; Barasa E
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35914832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden.
    Wolff E; Storsaeter J; Örtqvist Å; Naucler P; Larsson S; Lepp T; Roth A
    Vaccine; 2020 Jul; 38(32):4988-4995. PubMed ID: 32536548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 17. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S; Kim JJ
    PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.
    Atherly AJ; van den Broek-Altenburg EM
    BMC Health Serv Res; 2023 Apr; 23(1):372. PubMed ID: 37072753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.
    Mar J; Ibarrondo O; Estadilla CDS; Stollenwerk N; Antoñanzas F; Blasco-Aguado R; Larrañaga I; Bidaurrazaga J; Aguiar M
    Pharmacoeconomics; 2024 Feb; 42(2):219-229. PubMed ID: 37910377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.
    Shaker M; Abrams EM; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2658-2668.e3. PubMed ID: 33711496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.